Stock Information
Symbol
Nasdaq: CURPrice
Change
Volume
Market Cap
Day Low/High
52 week Low/High
Company Overview
Neuralstem is a biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. Our lead asset, NSI-189, is a new chemical entity in Phase 2 clinical development for major depressive disorder (MDD). Our transplantational stem cell asset, NSI-566, is a spinal cord-derived neural stem cell line being tested in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). These product candidates are based on the company’s proprietary neural stem cell technology.
Contact Information
Investor Relations
investor@neuralstem.com
Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
T: 718-921-8200
Auditor
Dixon Hughes Goodman LLP
809 Glen Eagles Court
Suite 200
Baltimore, MD 21286
T: 410-838-8000
F: 410-296-4815
Public Relations
investor@neuralstem.com